And that is where RUCONEST, apart from the fact that RUCONEST on the right-hand side here has a core segment of severely affected patients, which were unable to get proper results with other therapies, is -- that basically still represents our core of our business. RUCONEST now also finds itself to be treating more patients that are suffering from breakthrough attacks under the new prophylactic treatments that only suppress the bradykinin and kallikrein axis.
So therefore, we are optimistic and we remain optimistic, and you have seen it in the results of this year that we have a gradual recovery from the impact of COVID-19. We remain optimistic about continued growth of RUCONEST in the hereditary angioedema markets.
We also remain optimistic because of this picture here, what you see, it is indeed that, of course, a busy entry of new better prophylactic therapies, the shift in the U.S. market, as predicted, was moving towards prophylaxis. But we see that trend now as being sort of saturated. And therefore, those who were predicting that there was no place for acute therapies anymore with prophylaxis are actually proven to be not quite right because as you can see and as I was saying too earlier, every -- there needs to be acute treatments available even when you use prophylaxis because prophylactic therapies have breakthrough attacks, and they can be very unpredictable.
Bovenstaand stuk was de uitleg van Sijmen over het énige product dat Pharming verkoopt.
Met 'we remain optimistic' vind ik Sijmen erg twijfelachtig overkomen. In voorgaande calls (toen er nog groei te zien was) was Sijmen altijd veel overtuigender positief over de verkopen.